NCT03496233View on ClinicalTrials.gov

Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

May 20, 2020

Study Completion Date

June 20, 2020

Conditions
Chronic HCV Hepatitis
Interventions
DRUG

Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]

Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM

Trial Locations (1)

90127

Policlinico Paolo Giaccone, Palermo

All Listed Sponsors
lead

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

OTHER

NCT03496233 - Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients | Biotech Hunter | Biotech Hunter